leisure time -WSS

leisure time

author：comprehensive 2025-09-29 01:37:21 - browse：59739

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： HHS secretary Becerra pressed on Change HealthCare cyberattack

focus

entertainment

WSS

Fed up with FDA, ALS advocates consider a take

How the messy conversation about Dolly changed bioethics

Why the quest to eradicate polio has stumbled

Why depression after traumatic brain injury is distinct

Covid’s new normal has set in amid another rise in cases

FDA weighs limits of animal data in assessing artificial wombs

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Malaria cases in Florida and Texas: Here’s what you need to know

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Virginia high school admissions case could be legal follow

What happened to the House vote on health price transparency?

Medicare details structure of new drug price negotiation program

President Biden's budget: Here's what you might have missed

Psychedelics group wrestles with new pharma identity

Why depression after traumatic brain injury is distinct

leisure time

UCLA team creates talking throat patch for voice disorders

Senate bill would ban some hospital facility fees

First U.S. drug developed to treat liver disease MASH is approved

UCLA team creates talking throat patch for voice disorders

Covid’s new normal has set in amid another rise in cases

Patients, doctors press FTC to beef up hospital merger scrutiny

focus

entertainment

focus

focus